Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults

Nelson Lee, Chun Kwok Wong, Paul K S Chan, Martin C W Chan, Rity Y K Wong, Samantha W M Lun, Karry L K Ngai, Grace C Y Lui, Bonnie C K Wong, Sharon K W Lee, Kin Wing Choi, David S C Hui, Nelson Lee, Chun Kwok Wong, Paul K S Chan, Martin C W Chan, Rity Y K Wong, Samantha W M Lun, Karry L K Ngai, Grace C Y Lui, Bonnie C K Wong, Sharon K W Lee, Kin Wing Choi, David S C Hui

Abstract

Background: Studying cytokine/chemokine responses in severe influenza infections caused by different virus subtypes may improve understanding on pathogenesis.

Methods: Adults hospitalized for laboratory-confirmed seasonal and pandemic 2009 A/H1N1 (pH1N1) influenza were studied. Plasma concentrations of 13 cytokines/chemokines were measured at presentation and then serially, using cytometric-bead-array with flow-cytometry and ELISA. PBMCs from influenza patients were studied for cytokine/chemokine expression using ex-vivo culture (Whole Blood Assay,±PHA/LPS stimulation). Clinical variables were prospectively recorded and analyzed.

Results: 63 pH1N1 and 53 seasonal influenza patients were studied. pH1N1 patients were younger (mean±S.D. 42.8±19.2 vs 70.5±16.7 years), and fewer had comorbidities. Respiratory/cardiovascular complications were common in both groups (71.4% vs 81.1%), although severe pneumonia with hypoxemia (54.0% vs 28.3%) and ICU admissions (25.4% vs 1.9%) were more frequent with pH1N1. Hyperactivation of the proinflammatory cytokines IL-6, CXCL8/IL-8, CCL2/MCP-1 and sTNFR-1 was found in pH1N1 pneumonia (2-15 times normal) and in complicated seasonal influenza, but not in milder pH1N1 infections. The adaptive-immunity (Th1/Th17)-related CXCL10/IP-10, CXCL9/MIG and IL-17A however, were markedly suppressed in severe pH1N1 pneumonia (2-27 times lower than seasonal influenza; P-values<0.01). This pattern was further confirmed with serial measurements. Hypercytokinemia tended to be sustained in pH1N1 pneumonia, associated with a slower viral clearance [PCR-negativity: day 3-4, 55% vs 85%; day 6-7, 67% vs 100%]. Elevated proinflammatory cytokines, particularly IL-6, predicted ICU admission (adjusted OR 12.6, 95%CI 2.6-61.5, per log(10)unit increase; P = 0.002), and correlated with fever, tachypnoea, deoxygenation, and length-of-stay (Spearman's rho, P-values<0.01) in influenza infections. PBMCs in seasonal influenza patients were activated and expressed cytokines ex vivo (e.g. IL-6, CXCL8/IL-8, CCL2/MCP-1, CXCL10/IP-10, CXCL9/MIG); their 'responsiveness' to stimuli was shown to change dynamically during the illness course.

Conclusions: A hyperactivated proinflammatory, but suppressed adaptive-immunity (Th1/Th17)-related cytokine response pattern was found in severe pH1N1 pneumonia, different from seasonal influenza. Cytokine/immune-dysregulation may be important in its pathogenesis.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Serial changes in plasma cytokine/chemokine…
Figure 1. Serial changes in plasma cytokine/chemokine concentrations during the course of hospitalization.
There was sustained elevation of the proinflammatory cytokines (IL-6, CXCL8/IL-8, CCL2/MCP-1, sTNFR-1) in severe pH1N1 pneumonia; the adaptive-immunity related cytokines (CXCL10/IP-10, CXCL9/MIG, IL-17A) were markedly suppressed compared with seasonal influenza. All patients with pH1N1 influenza (severe pneumonia, n = 34; milder illness, n = 29) received antiviral treatment soon after hospitalization/recruitment; none had received high-dose corticosteroids or other immunosuppressants for ‘viral pneumonitis’ or ‘ARDS’. Among seasonal influenza patients (most had complicated illnesses, see Table 1 footnotes), 30(57%) received antiviral treatment. Median concentrations at each time point are shown for each group; the interquartile ranges (presented in Table 1) are omitted here for clarity. Fewer mild pH1N1 and untreated seasonal influenza patients remained hospitalized at day 6–7 for study (Day 1, n = 116; Day 3–4, n = 62; Day 6–7, n = 30).
Figure 2. PBMC activation and ex vivo…
Figure 2. PBMC activation and ex vivo cytokine/chemokine expression during seasonal influenza infection.
PBMC actively expressed IL-6, (CXCL8/IL-8), CCL2/MCP-1, CXCL10/IP-10, and CXCL9/MIG during acute influenza infection; upon illness recovery, cytokine production decreased, and there was a corresponding increase in cellular responsiveness to stimuli. Cytokine response pre-/post-stimulation and the trend changes in cytokine expression across time points (with PHA/LPS stimulation – red bars; without stimulation – blue bars; folds increase in expression or the ‘responsiveness’ – gray bars) were compared using the Mann-Whitney U test (asterisks, underlined), and the Jonckheere-Terpstra test (blue/gray triangles and asterisks), respectively. IL-17A did not appear to be activated via the PHA/LPS stimulation pathway.

References

    1. World Health Organization. Influenza. 1 Available . Accessed 2011 May.
    1. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708–1719.
    1. Centre for Health Protection. . Department of Health, The Government of the Hong Kong SAR. 1 Available . Accessed 2011 May.
    1. Ison MG, Lee N. Influenza 2010-2011: lessons from the 2009 pandemic. Cleve Clin J Med. 2010;77:812–820.
    1. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935–1944.
    1. Louie JK, Acosta M, Winter K, Jean C, Gavali S, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896–1902.
    1. Lee N, Chan PK, Lui GC, Wong BC, Sin WW, et al. Complications and Outcomes of Pandemic 2009 Influenza A (H1N1) Virus Infection in Hospitalized Adults – how are they Different from Seasonal Influenza? J Infect Dis. 2011;203:1739–1747.
    1. Lee N, Chan PK, Wong CK, Wong KT, Choi KW, et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther. 2011;16:237–247.
    1. To KK, Hung IF, Li IW, Lee KL, Koo CK, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850–859.
    1. van den Brand JM, Stittelaar KJ, van Amerongen G, Rimmelzwaan GF, Simon J, et al. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis. 2010;201:993–999.
    1. Geiler J, Michaelis M, Sithisarn P, Cinatl J Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses. Med Microbiol Immunol. 2011;200:53–60.
    1. Chan MC, Chan RW, Yu WC, Ho CC, Yuen KM, et al. Tropism and innate host responses of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of human conjunctiva and respiratory tract. Am J Pathol. 2010;176:1828–1840.
    1. Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol. 2009;30:574–584.
    1. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. . J Infect Dis. 2009;200:492–500.
    1. Lee N, Wong CK, Chan PK, Lun SW, Lui G, et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis. 2007;45:723–731.
    1. Lit LCW, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Annals Rhe Dis. 2006;65:209–215.
    1. Rigato O, Salomao R. Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock. 2003;19:113–116.
    1. Hussain R, Kaleem A, Shahid F, Dojki M, Jamil B, et al. Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population. J Immunol Methods. 2002;264:95–108.
    1. Hagau N, Slavcovici A, Gonganau DN, Oltean S, Dirzu DS, et al. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care 14:R203. Epub 2010 Nov. 2010;9
    1. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009;13:R201.
    1. Bermejo-Martin JF, Martin-Loeches I, Rello J, Antón A, Almansa R, et al. Host adaptive immunity deficiency in severe pandemic influenza. Crit Care. 2010;14:R167.
    1. Sato M, Hosoya M, Wright PF. Differences in serum cytokine levels between influenza virus A and B infections in children. Cytokine. 2009;47:65–68.
    1. Svitek N, Rudd PA, Obojes K, Pillet S, von Messling V. Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction. Virology. 2008;376:53–59.
    1. Wu W, Booth JL, Duggan ES, Wu S, Patel KB, et al. Innate immune response to H3N2 and H1N1 influenza virus infection in a human lung organ culture model. Virology. 2010;396:178–188.
    1. McGill J, Heusel JW, Legge KL. Innate immune control and regulation of influenza virus infections. J Leukoc Biol. 2009;86:803–812.
    1. Arankalle VA, Lole KS, Arya RP, Tripathy AS, Ramdasi AY, et al. PLoS One 5(10). pii; 2010. Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients.e13099
    1. Longhi MP, Wright K, Lauder SN, Nowell MA, Jones GW, et al. Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog. 2008;4(2):e1000006.
    1. Lee SM, Chan RW, Gardy JL, Lo CK, Sihoe AD, et al. Systems-level comparison of host responses induced by pandemic and seasonal influenza A H1N1 viruses in primary human type I-like alveolar epithelial cells in vitro. Respir Res. 2010;11:147.
    1. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203–1207.
    1. Osterlund P, Pirhonen J, Ikonen N, Rönkkö E, Strengell M, et al. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol. 2010;84:1414–1422.
    1. Agrati C, Gioia C, Lalle E, Cimini E, Castilletti C, et al. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis. 2010;202:681–689.
    1. Jiang TJ, Zhang JY, Li WG, Xie YX, Zhang XW, et al. Preferential loss of Th17 cells is associated with CD4 T cell activation in patients with 2009 pandemic H1N1 swine-origin influenza A infection. Clin Immunol. 2010;137:303–310.
    1. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–898.
    1. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, et al. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol. 2009;183:5301–5310.
    1. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol. 2011;186:1666–1674.
    1. Hamada H, Garcia-Hernandez Mde L, Reome JB, Misra SK, Strutt TM, et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol. 2009;182:3469–3481.
    1. Giamarellos-Bourboulis EJ, Raftogiannis M, Antonopoulou A, Baziaka F, Koutoukas P, et al. Effect of the novel influenza A (H1N1) virus in the human immune system. PLoS One. 2009;4(12):e8393.
    1. Rowe T, León AJ, Crevar CJ, Carter DM, Xu L, et al. Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology. 2010;401:257–265.
    1. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A. 2009;106:3455–3460.
    1. Han K, Ma H, An X, Su Y, Chen J, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53:326–333.
    1. Brun-Buisson C, Richard JC, Mercat A, Thiébaut AC Brochard L; for the REVA-SRLF A/H1N1v 2009 Registry Group. Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2011;183:1200–1206.
    1. Lee N, Hui DS. Lancet. In press; 2011. Corticosteroids in community-acquired pneumonia.
    1. Simmons C, Farrar J. Insights into inflammation and influenza. N Engl J Med. 2008;359:1621–1623.
    1. Hui DS, Lee N, Chan PK. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest. 2010;137:916–925.
    1. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108:12018–12023.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe